Table 5.
Mean OCT Neuroretinal Rim, Perineural Canal Retinal Nerve Fiber Layer Thickness (pNC-RNFLT), Neural Canal, and Perineural Canal Choroidal Thickness (pNC-CT) Parameter Values of Study Participants for the Highly Myopic Healthy (Hi-Myo-Healthy) and Highly Myopic Glaucomatous (Hi-Myo-GL) Eyes.
| Hi-Myo Eyes (n=122) | ||||||
|---|---|---|---|---|---|---|
|
| ||||||
| Hi-Myo-Healthy Eyes (n=64) | Hi-Myo-GL Eyes (n=58) | |||||
|
| ||||||
| All Eyes (n=64) | Non-Hi-ESF Eyes (n=17) | Hi-ESF Eyes (n=47) | All Eyes (n=58) | Non-Hi-ESF Eyes (n=18) | Hi-ESF Eyes (n=40) | |
| Global BMO-MRW (μm ± SD, (range)) | 292.1 ± 63.8 (175.7 to 414.6) | 320.4 ± 69.1 (194.8 to 414.6) | 281.9 ± 59.2 (175.7 to 397.0) | 173.5 ± 44.5*** (96.6 to 302.3) | 162.8 ± 52.7*** (107.0 to 302.3) | 178.3 ± 40.1*** (96.6 to 270.0) |
| Global pNC-RNFLT (12 degree) (μm ± SD, (range)) | 87.8 ± 14.9 (55.3 to 116.5) | 91.1 ± 15.7 (55.3 to 116.5) | 86.6 ± 14.6 (62.4 to 116.3) | 63.5 ± 13.1*** (43.3 to 103.2) | 63.6 ± 12.5*** (46.2 to 96.0) | 63.4 ± 13.5*** (43.3 to 103.2) |
| BMO area (mm2 ± SD, (range)) | 2.39 ± 0.78 (1.14 to 4.32) | 2.00 ± 0.41 (1.14 to 2.69) | 2.53 ± 0.84** (1.22 to 4.32) | 2.25 ± 0.82 (1.07 to 5.42) | 2.08 ± 0.70 (1.07 to 3.98) | 2.34 ± 0.86 (1.32 to 5.42) |
| ASCO area (mm2 ± SD, (range)) | 2.44 ± 0.70 (0.89 to 3.81) | 2.32 ± 0.57 (1.24 to 3.52) | 2.48 ± 0.74 (0.89 to 3.81) | 2.29 ± 0.78 (1.23 to 5.21) | 2.25 ± 0.71 (1.28 to 4.13) | 2.31 ± 0.81 (1.23 to 5.21) |
| BMO/ASCO area ratio (± SD, (range)) | 1.00 ± 0.23 (0.59 to 1.99) | 0.88 ± 0.14 (0.66 to 1.22) | 1.04 ± 0.24** (0.59 to 1.99) | 0.99 ± 0.17 (0.69 to 1.55) | 0.93 ± 0.17 (0.75 to 1.49) | 1.02 ± 0.17 (0.69 to 1.55) |
| SFO area (mm2 ± SD, (range)) | 2.23 ± 0.64 (0.82 to 3.66) | 2.27 ± 0.59 (1.24 to 3.52) | 2.22 ± 0.66 (0.82 to 3.66) | 2.08 ± 0.68 (1.03 to 4.30) | 2.21 ± 0.72 (1.25 to 4.13) | 2.03 ± 0.66 (1.03 to 4.30) |
| NCMCA (mm2 ± SD, (range)) | 0.85 ± 0.45 (0.26 to 2.35) | 1.09 ± 0.57 (0.32 to 2.18) | 0.76 ± 0.36 (0.26 to 2.35) | 0.88 ± 0.56 (0.24 to 3.19) | 1.10 ± 0.63 (0.42 to 2.66) | 0.77 ± 0.50 (0.24 to 3.19) |
| BMO ovality index (± SD, (range)) | 1.13 ± 0.09 (1.01 to 1.36) | 1.13 ± 0.08 (1.01 to 1.31) | 1.13 ± 0.09 (1.01 to 1.36) | 1.11 ± 0.07 (1.01 to 1.28) | 1.13 ± 0.09 (1.01 to 1.28) | 1.10 ± 0.06 (1.02 to 1.25) |
| ASCO ovality index (± SD, (range)) | 1.14 ± 0.09 (1.01 to 1.40) | 1.15 ± 0.10 (1.02 to 1.30) | 1.13 ± 0.08 (1.01 to 1.40) | 1.13 ± 0.08 (1.00 to 1.36) | 1.16 ± 0.10 (1.00 to 1.36) | 1.12 ± 0.07 (1.01 to 1.28) |
| SFO ovality index (± SD, (range)) | 1.19 ± 0.12 (1.01 to 1.63) | 1.17 ± 0.11 (1.04 to 1.34) | 1.19 ± 0.13 (1.01 to 1.63) | 1.18 ± 0.12 (0.94 to 1.57) | 1.17 ± 0.10 (1.00 to 1.35) | 1.19 ± 0.12 (0.94 to 1.57) |
| NCMCA ovality index (± SD, (range)) | 2.86 ± 1.03 (1.11 to 6.09) | 2.24 ± 1.10 (1.11 to 4.84) | 3.08 ± 0.91 (1.74 to 6.09) | 2.71 ± 1.06 (1.12 to 6.52) | 2.06 ± 0.61 (1.12 to 3.04) | 2.99 ± 1.09*** (1.12 to 6.52) |
| BMO / ASCO offset magnitude (μm ± SD, (range)) | 284.55 ± 140.12 (23.00 to 724.00) | 176.59 ± 113.79 (23.00 to 506.00) | 323.60 ± 128.53*** (60.00 to 724.00) | 218.66 ± 106.57 (29.00 to 509.00) | 144.06 ± 85.94 (29.00 to 310.00) | 252.23 ± 98.25*** (42.00 to 509.00) |
| BMO / SFO offset magnitude (μm ± SD, (range)) | 348.31 ± 175.33 (31.00 to 938.00) | 192.47 ± 119.81 (31.00 to 524.00) | 404.68 ± 157.75*** (84.00 to 938.00) | 283.17 ± 142.54 (29.00 to 697.00) | 158.83 ± 93.24 (29.00 to 322.00) | 339.13 ± 124.74*** (129.00 to 697.00) |
| Neural Canal Obliqueness (degree ± SD, (range)) | 66.02 ± 12.67 (16.00 to 83.00) | 54.77 ± 17.28 (16.00 to 80.00) | 70.09 ± 7.23** (47.00 to 83.00) | 64.52 ± 14.73 (16.00 to 81.00) | 55.94 ± 17.24 (19.00 to 74.00) | 68.38 ± 11.76 (16.00 to 81.00) |
| Global pNC-CT 100 (μm ± SD, (range)) | 106.31 ± 25.54 (55.89 to 163.86) | 107.84 ± 23.10 (69.07 to 150.88) | 105.76 ± 26.59 (55.89 to 163.86) | 90.27 ± 30.85** (34.45 to 189.58) | 85.40 ± 28.95 (34.45 to 126.96) | 92.46 ± 31.78 (43.44 to 189.58) |
| Page 42 Global pNC-CT 300 (μm ± SD, (range)) | 108.08 ± 28.73 (48.31 to 169.35) | 114.67 ± 27.81 (62.94 to 154.37) | 105.70 ± 28.97 (48.31 to 169.35) | 93.85 ± 30.14 (35.08 to 163.88) | 95.12 ± 33.05 (35.08 to 144.21) | 93.27 ± 29.17 (40.17 to 163.88) |
| Global pNC-CT 700 (μm ± SD, (range)) | 110.69 ± 33.66 (46.67 to 184.56) | 127.01 ± 36.67 (50.48 to 184.56) | 104.79 ± 29.50 (46.67 to 182.45) | 95.92 ± 31.74 (38.24 to 171.73) | 102.30 ± 37.68 (39.95 to 171.73) | 93.05 ± 28.74 (38.24 to 168.77) |
| Global pNC-CT 1100 (μm ± SD, (range)) | 112.12 ± 37.66 (50.33 to 192.43) | 133.41 ± 46.89 (50.33 to 192.43) | 104.42 ± 30.82 (54.70 to 186.07) | 96.68 ± 34.55 (35.22 to 185.45) | 105.71 ± 39.86 (43.28 to 185.45) | 92.61 ± 31.58 (35.22 to 176.14) |
Data for each group are reported for “All Eyes” as well as for “Hi-ESF and for “Non-Hi-ESF” sub-groups (Hi-ESF eyes defined to be those eyes in which the magnitude of the ESF subregion was ≥ 100 μm in at least one ONH sector – (see Methods). Within the Hi-Myo eyes (Right Panel), data in bold red with red asterisks are significantly different from the Non-Hi-Myo value (Left Panel) for the same sub-group and remain significant using a Holm-Bonferonni correction for multiple comparisons
(p < 0.001
p < 0.01
p < 0.05, t test). Within the Hi-ESF column of both groups, black asterisks denote data that are significantly different from the Non-Hi-ESF eyes of the same group and remain significant using a Holm-Bonferonni correction for multiple comparisons
(p < 0.001
p < 0.01
p < 0.05, t test).